Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of OATP1B blockade with rifampicin on sorafenib pharmacokinetics in adults with cancer
NL-OMON23851Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sorafenib in Nonhematologic neoplasms (2 arms), sponsored by Erasmus MC. Primary endpoint: Sorafenib pharmacokinetics with and without rifampicin-mediated OATP1B inhibition. Started Aug 2013; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON23851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23851.